Memorandum

Subject	Date
Initial 2010 Procurement Quota Letter as of 12/07/09 (DFN:	DEC 15 2009

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boeckholdt, Chief
Regulatory Section
Office of Diversion Control

On December 07, 2009, this section received your e-mail requesting a review of one hundred and ninety seven (197) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc) as well as surveyed the responsible field offices for their input and advisement. Provided below are the results and recommendations.

There was no derogatory information found, with the exception of the following:

(b)(4);(b)(7)(E)	Currently under review/investigation
	Currently under review/investigation
	Retired
	Per New York, this location is closing in 1/2010 and/or 2/2010 no quota is needed
	OTSC placed against registration 10/30/08 Settlement discussions are ongoing.
	Currently under review/investigation
	Currently under review/investigation
	Currently under review/investigation
	Currently under review/investigation

(b)(4);(b)(7)(E) Retired

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the one hundred and ninety seven (197) quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Attachments:
Email Request and Responses

Memorandum

Subject

Controlled Substance Quota Requests for 2010
Initial Quotas for 12/22/2009
(DFN:630-08.2)

Date

December, 24, 2009

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On December 22, 2009, this section received your e-mail requesting a review of seven (7) quota applications, to determine if there is any pending administrative/legal action against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc) as well as surveyed the responsible field offices for their input and advisement. Provided below are the results and recommendations.

There was no derogatory information found on any of the applicants.

Abbott Pharmaceuticals PR LTD
Med Shop Total Care Pharmacy
Novartis Pharmaceutical Corp
Research Triangle Institute
Sigma Aldrich Research
Tedor Pharma
Tris Pharma Inc

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the above stated quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Attachments:
Email Request

(b)(6);(b)(7)(C)

From: (b)(6);(b)(7)(C)
Sent: Tuesday, December 22, 2009 2:00 PM
To: Boockholdt, Barbara J.; (b)(6);(b)(7)(C)
Cc: (b)(6);(b)(7)(C) (b)(6);(b)(7)(C) Sannerud, Christine A
Subject: additional initial 2010 quota applications received as of 12/22/09

Good afternoon Barbara,

Below is a list of quota applications from DEA-registered manufacturers received as of December 22, 2009.

We request that ODG review for pending administrative/legal action against these applicants and advise ODE of your findings.

Thanks in advance!

Company Name	Registration #
Abbott Laboratories North Chicago	(b)(4);(b)(7)(E)
Med Shop Total Care Pharmacy	
Novartis Pharmaceutical Corporation	
Research Triangle Research 1	
Sigma-Aldrich Research Biochemicals	
Tedor Pharma Inc.	
Tris Pharma, Inc.	

Drug Science Specialist
ODEQ

Phone: (b)(6);(b)(7)(C)
Fax: (b)(6);(b)(7)(C)
e-mail: (b)(6);(b)(7)(C) @USDOJ.gov

DEA Headquarters
Attn: Drug & Chemical Evaluation Section/ODE
8701 Morrissette Drive
Springfield, Virginia 22152

Memorandum

Subject	Date
Quota Requests as of January 6, 2010 (DFN: 630-08.2)	JAN 16 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On January 7, 2010, this section received your e-mail requesting a review of thirty-three (33) quota applications from twenty-eight (28) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Denison Pharmaceuticals (9517)
RIJ Pharmaceutical (9518)
Aputit (9519)
Anderson Packaging, Inc. (9520)
Fisher (9521)
Cody Laboratories (9522)
Boehringer Ingelhelm (9524)
Noramco Georgia (9525)
Noramco Delaware (9526)
Archimica (9527)
Lehigh Valley Technologies, Inc. (9528)
Rhodes (9529)
AMRI (9530)
Cedarburg (9531)
Chattem (9532)
Chattem (9533)
Sigma Aldrich (9534)
Noramco Georgia (9535)
Mallinckrodt St. Louis (9536)
Norac (9537)

(b)(4);(b)(7)(E)

PalliRx, Inc. (9538)
Contract Pharmacal Corp (9540)
ANIP (9541)
ANIP (9542)
ANIP (9543)
National Center (9544) (1 of 2)
Upsher-Smith (9545)
Rhodes (9546)
Catalent (9547)
Cerilliant (9548)
Pharmedium (9549) (1 of 2)

(b)(4);(b)(7)(E)

QUOTA APPLICANTS WITH ADVERSE OR DEROGATORY INFORMATION

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

Expired – Currently authorized to conduct business as usual with the expired license until a decision is reached on the registration

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

5/1/2010

Subject	Date
Additional Quota Requests as of January 11, 2010 (DFN: 630-08.2)	JAN 16 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On January 11, 2010, this section received your e-mail requesting a review of eleven (11) quota applications from nine (9) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Elite (9550)
Dispensing Solutions, Inc. (9551)
Palmetto State Pharmaceuticals (9552)
Mallinckrodt Webster Groves (9553)
Amerisource (9554)
Mallinckrodt St. Louis (9555)
Azopharma (9556)
Sharp (9557)
Sharp (9558)
Sharp (9559
Norwich (9560)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

S 1/26/10

Memorandum

Subject	Date
Quota Requests as of January 6, 2010 (DFN: 630-08.2)	JAN 16 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On January 7, 2010, this section received your e-mail requesting a review of thirty-three (33) quota applications from twenty-eight (28) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Denison Pharmaceuticals (9517)
RIJ Pharmaceutical (9518)
Aputit (9519)
Anderson Packaging, Inc. (9520)
Fisher (9521)
Cody Laboratories (9522)
Boehringer Ingelhelm (9524)
Noramco Georgia (9525)
Noramco Delaware (9526)
Archimica (9527)
Lehigh Valley Technologies, Inc. (9528)
Rhodes (9529)
AMRI (9530)
Cedarburg (9531)
Chattem (9532)
Chattem (9533)
Sigma Aldrich (9534)
Noramco Georgia (9535)
Mallinckrodt St. Louis (9536)
Norac (9537)

(b)(4);(b)(7)(E)

PalliRx, Inc. (9538)
Contract Pharmacal Corp (9540)
ANIP (9541)
ANIP (9542)
ANIP (9543)
National Center (9544) (1 of 2)
Upsher-Smith (9545)
Rhodes (9546)
Catalent (9547)
Cerilliant (9548)
Pharmedium (9549) (1 of 2)

(b)(4);(b)(7)(E)

QUOTA APPLICANTS WITH ADVERSE OR DEROGATORY INFORMATION

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

Expired - Currently authorized to conduct business as usual with the expired license until a decision is reached on the registration

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

5/1/24/10

Subject	Date
Additional Quota Requests as of January 14, 2010 (DFN: 630-08.2)	JAN 20 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On January 14, 2010, this section received your e-mail requesting a review of eighteen (18) quota applications from eleven (11) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Alza (9562)
Sovereign (9563)
Glatt Air (9564)
Glatt Air (9565)
Cambrex (9566)
Siemens Healthcare Diagnostics Inc. (9569)
AAIPharma (9570)
AAIPharma (9571)
AAIPharma (9572)
Norwich (9573)
Norwich (9574)
Norwich (9575)
AAIPharma (9576)
Novartis Consumer Health Lincoln (9577)
Hisamitsu (9578)
Fisher (9579)
United Liquid (9580)
Fisher (9591)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

5-17-2010

Memorandum

Subject	Date
Additional Quota Applications Received through January 20, 2010 (DFN: 630-08.2)	JAN 22 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On January 20, 2010, this section received your e-mail requesting a review of twenty-two (22) quota applications from twenty-one (21) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Cerilliant (9597)
Cambrex (9598)
Noramco (9599)
Ohm Laboratories (9600)
Mallinckrodt St. Louis (9601)
Norac (9602)
Bayer (9603)
AAIPharma (9604)
Boehringer Ingelheim (9605) (1 of 2)
Actavis (9606)
Purdue (9607)
Johnson Matthey (9608)
Mikart (9609)
Quality Assurance (9612)
Sharp Corporation (9613)
DSM (9614)
Anderson Packaging, Inc. (9615)
Anderson Packaging, Inc. (9616)
Epic Pharma (9617)
Impax Laboratories, Inc. (9618)(1 of 2)
Impax Laboratories, Inv. (9618)(2 of 2)

(b)(4);(b)(7)(E)

ODGR is waiting for further clarification/response from the responsible field office for the below stated manufacture. Updated information will be provided upon receipt.

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Additional Quota Applications Received through January 20, 2010
(DFN: 630-08.2)

Date

MAR 17 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diversion Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

Reference is made to a memorandum submitted to your office on January 22, 2010 regarding the above stated subject matter. This memorandum serves to update the response from the responsible field office. This section submitted one (1) registrant whose quota request information was pending field review.

This office conducted a review (NADDIS, CSA, etc.) as well as surveyed the responsible field office for their input and advisement. Provided below are the result and recommendation:

QUOTA APPLICANT WITH NO ADVERSE OR DEROGATORY INFORMATION

Boehringer Ingelheim Vetmedica, Inc. (b)(4);(b)(7)(E)

ODG recommends approval of Boehringer's quota request.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

BEST AVAILABLE COPY

Memorandum

Subject
Additional Quota Requests as of January 25, 2010
(DEN: 630-08.2)

Date
JAN 27 2010

To
Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From
Barbara J. Boeckholdt, Chief
Regulatory Section
Office of Diversion Control

On January 25, 2010, this section received your e-mail requesting a review of fourteen (14) quota applications from eleven (11) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Sharp Corporation (9619)
Elsohyl Laboratories (9621)
Noramco (9625)
Micron Technologies, Inc. (9626)
Safecor (9627)
Austin Pharma (9628)
Sigma-Aldrich (9629)
Eminenet (9634)
Siegfried (9635)
Siegfried (9636)
Siegfried (9637)
Watson (9638)
Watson (9639)
AAIPharma (9640)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Requests as of January 28, 2010 (DFN: 630-08.2)	FEB 0 5 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On January 28, 2010, this section received your e-mail requesting a review of nine (09) quota applications from eight (08) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Pharmacia & Upjohn (9646)
Sharp Corporation (9647)
Pharmaceutical Manufacturing Research Services (9648)
Catalent (9649)
Pharmaceutics International (9650)
Deltex (9655)
Consolidated (9656)
Ameridose, LLC (9658)
Ameridose, LLC (9659)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of February 1, 2010 (DFN: 630-08.2)	FEB 02 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On February 1, 2010, this section received your e-mail requesting a review of thirteen (13) quota applications from seven (07) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Unit Dose Solutions (9663)
Unit Dose Solutions (9664)
Unit Dose Solutions (9665)
Unit Dose Solutions (9666)
Unit Dose Solutions (9667)
Unit Dose Solutions (9668)
Unit Dose Solutions (9669)
Novartis (9676)
Mylan (9679)
Deltex (9671)
Chattem (9674)
Anderson Packaging, Inc. (9675)
Alaunus Pharmaceutical (9678)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Requests as of February 4, 2010 (DFN: 630-08.2)	FEB 0 4 2010

To	From
Christine A. Sannerud, Ph.D., Chief Drug & Chemical Evaluation Section Office of Diverison Control	Barbara J. Boockholdt, Chief Regulatory Section Office of Diversion Control

On February 4, 2010, this section received your e-mail requesting a review of ten (10) quota applications from registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Actavis (9677)
GE Healthcare (9680)
AAIPharma (9681)
Baxter (9682)
Dispensing Solutions, Inc. (9683)
Impax (9684)
Sun Pharmaceuticals (9685)
Rhodes (9686)
Sigma-Aldrich (9687)
Halo (9688)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of February 18, 2010 (DFN: 630-08.2)	FEB 19 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On February 18, 2010, this section received your e-mail requesting a review of thirty-seven (37) quota applications from twenty-two (22) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Stepan (9692)
Purdue (9693)
St. Mary's Medical Park Pharmacy (9695)
Glatt Air (9696)
Aputit (9699)
Mylan (9700)
Eminent (9702)
Siegfried (9703)
Mallinckrodt St. Louis (9705)
Mallinckrodt St. Louis (9706)
Fisher (9708)
Fisher (9709)
Nektar (9710)
Nektar (9711)
Noven (9712)
Noven (9713)
Noven (9714)
Noven (9715)
Noven (9716)
Noven (9717)

(b)(4);(b)(7)(E)

Noven (9718)
Cantrell Drug Company (9719)
Pfizer (9720)
Amneal (9721)
Fisher (9722)
Cody Laboratories (9724)
Coating Place Inc. (9725)
DSM (9726)
Cody Laboratories (9728)
Mallinckdrodt (9729)
Fisher (9528) 9730
Gorbec Pharmaceutical Svcs (9733)
DPT (9734)
Amneal (9735)
Purdue (9737)
Glatt Air (9738)
Purdue (9739)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

5/3/3/10

Memorandum

Subject

Additional Quota Letters Received as of February 25, 2010
(DFN: 630-08.2)

Date

MAR 0 3 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On February 25, 2010, this section received your e-mail requesting a review of thirty-five (35) quota applications from twenty-six (26) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Mylan (9741)
Amneal (9743)
Med Pharmex (9744)
AAIPharma (9745)
Par Pharmaceuticals (9746)
Physicians Total Care (9747)
Classic Pharmaceuticals (9748)
Coating Place Inc. (9752)
Mallinckrodt St. Louis (9753)
St. Mary's (9754)
St. Mary's (9755)
St. Mary's (9756)
St. Mary's (9757)
St. Mary's (9758)
St. Mary's (9759)
Metrics (9761)
Metrics (9763)
Restek (9764)
Mikart (9765) (1of2)
Mikart (9765) (2of2)

(b)(4);(b)(7)(E)

Mallinckrodt St. Louis (9766)
Nucare (9769)
Aurolife (9770)
Sharp Corporation (9771)
Mylan (9772) (1 of 2)
Mylan (9772) (2 of 2)
Johnson Matthey (9773)
King Pharmaceuticals (9775)
Watson (9776)
Lannett (9777) (1 of 2)
Lannett (9777) (2 of 2)
St. Mary's (9778)
Neos Therapeutics, LP (formerly Pharmafab) (9781)
AAIPharma (9782)
Rhodes (9784)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

5/31/11

Memorandum

Subject	Date
Additional Quota Requests as of March 1, 2010 (DFN: 630-08.2)	MAR 0 3 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On March 2, 2010, this section received your e-mail requesting a review of eight (08) quota applications from six (06) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Barr Laboratories (9786)
Acura Pharmaceutical Technologies (9787)
Dispensing Solutions, Inc. (9788)
Nexgen Pharma, Inc. (9790)
Coating Place, Inc. (9791)
Aptuit (9792)
Aptuit (9793)
Aptuit (9794)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Requests as of March 8, 2010 (DFN: 630-08.2)	MAR 11 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On March 8, 2010, this section received your e-mail requesting a review of eighteen (18) quota applications from sixteen (16) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Penick (9801)
National Center (9802)
Noramco Delaware (9803)
Dispensing Solutions, Inc. (9804)
Banyan (9805)
Supelco (9807)
Vintage Generics Bidco (9808)
Vintage (9809)
Spectrum (9811)
Pharmaceutics International (9814)
Pharmaceutics International (9815)
Boehringer Ingelheim (9818)
TG United Liquid (9819)
Barr (9821)
Sigma-Aldrich (9822)
Mallinckrodt St. Louis (9825)
Noramco Delaware (9826)
Fisher (9828)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letter Received as of March 15, 2010 (DFN: 630-08.2)	MAR 16 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On March 15, 2010, this section received your e-mail requesting a review of twenty-seven (27) quota applications from twenty-four (24) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Siegfried (9704)
Noramco Delaware (9831)
Noramco Delaware (9832)
Noramco Georgia (9833)
Shire (9834)
Activis (9836)
Norwich (9837)
Neos Therapeutics, LP (9839)
Neos Therapeutics, LP (9840)
Neos Therapeutics, LP (9841)
Gallipot (9842)
Hisamitsu California Laboratories (9843)
Chattem (9844)
DSM (9845)
Cerilliant (9847)
Mylan (9848)
Hi-tech (9849)
Fisher (9850)
TEVA (9853)
Epic (9854)

(b)(4);(b)(7)(E)

Cody (9855)
Akorn (9857)
Varian (9860)
Mallinckrodt (9861)
National Center for Natural Products Research (9862)
Professional Compounding (9863)
Banner (9864)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of March 22, 2010 (DFN: 630-08.2)	MAR 24 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On March 22, 2010, this section received your e-mail requesting a review of twenty-three (23) quota applications from twenty (20) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Pharmaceutics International (9871)
Watson (9872)
Med Shop Total Care (9873)
Fisher (9875)
Shire (9876)
Barr (9877)
Barr (9878)
DSM (9879)
Paddock (9880)
Actavis (9606)
Barr (9882)
Barr (9883)
Barr (9884)
Glatt Air (9885)
Microgenics (9886)
Almact (9887)
VistaPharm (9888)
Epic (9889)
Acura (9890)
Nexgen Pharma Inc.(9891)

(b)(4);(b)(7)(E)

Ameridose, LLC (9892)(1 of 2)
Ameridose, LLC (9892)(2 of 2)
Central Admixture (9893)
Schwarz Pharma (9894)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of March 29, 2010 (DFN: 630-08.2)	MAR 30 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On March 29, 2010, this section received your e-mail requesting a review of twenty-four (24) quota applications from twenty-two (22) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Mylan (9866)
Pharmaceutics International (9874)
St. Mary's (9896)
Norac (9898)
Lonza (9899)
Purdue (9900)
Par Pharmaceutical (9901)
Letco Medical (9902)
Amcor (9903)
Pharmaceutics International (9904)
Coating Place Inc (9905)
Par Pharmaceuticals (9906)
Anderson Packaging, Inc (9907)
Watson (9908)
Corepharma (9909)
Aurolife (9910)
Mikart (9912)
Spectrum (9913)
Johnson Matthey (9916)
King Pharmaceuticals (9917)

(b)(4);(b)(7)(E)

Sandoz (9918)
Metrics (9921)
Metrics (9922)
Patheon (9923)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Additional Quota Letters Received as of April 5, 2010
(DFN: 630-08.2)

Date

APR 1 2 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On April 5, 2010, this section received your e-mail requesting a review of sixteen (16) quota applications from fifteen (15) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Johnson Matthey (9928)
Amneal (9929)
Barr (9930)
Noramco (9931)
Pharmedium (9932)(2 of 2)
Siegfried (9933)
Watson (9837)(1 of 2)
Watson (9837)(2 of 2)
Lannett (9938)(1 of 2)
Lannett (9938)(2 of 2)
Cambrex (9939)
Consolidated (9941)
Safecor Health, LLC (9943)
(Regional Service Center)
Patheon (9944)
Cambrex (9945)

(b)(4);(b)(7)(E)

QUOTA APPLICANT WITH ADVERSE OR DEROGATORY INFORMATION

(b)(4);(b)(7)(E)

(b)(4);(b)(5);(b)(6);(b)(7)(C)

Currently under review/investigation

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Additional Quota Letters Received as of April 19, 2010
(DFN: 630-08.2)

Date

MAY 10 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On April 19, 2010, this section received your e-mail requesting a review of fifty-two (52) quota applications from thirty (30) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

AMRI (9950)
AMRI (9951)
AMRI (9952)
AMRI (9953)
AMRI (9954)
AMRI (9955)
Vintage (9957)
Janssen Cilag (9958)
Cody (9959)
Cody (9960)
Nexgen Pharma, Inc. (9962)
Sharp Corporation (9963)
Siegfried (9964)
Siegfried (9965)
Siegfried (9966)
Siegfried (9967)
Siegfried (9968)
Siegfried (9969)
CIMA (9970)
Sandoz (9972)

(b)(4);(b)(7)(E)

Mylan (9973)
Actavis Mid-Atlantic (9977)
Arista (9978)
Formurex (9979)
Noramco Delaware (9981)
Noramco Delaware (9982)
King (9983)
Watson Corona (9986)
Watson Corona (9987)
Watson Corona (9988)
Watson Corona (9989)
Watson Corona (9990)
Amneal (9991)
TEVA (9992)
Cody (9993)
Hospira, Inc. KS (9994)
Mallinckrodt Webster Groves (9995)
Noramco Delaware (9997)
Cody (10000)
Akorn S. Wyckies (10001)
Aurolife Pharma LLC (10002)
B&B (10003)
Mylan (10004)
Medisca (10005)
HiTech (10007)
Noramco Georgia (10008)
Fisher (10010)
Mylan (10013)
Aurolife (10014)
Tedor Pharma Inc. (10015)
Hisamitsu (10016)
Hisamitsu (10017)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Additional Quota Letters Received as of April 29, 2010
(DFN: 630-08.2)

Date

MAY 10 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On April 29, 2010, this section received your e-mail requesting a review of forty (40) quota applications from thirty-two (32) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

AAIPharma (10040)
Akorn (10023)
Baxter (10035)
Bilcare (10025)
Boehringer Ingelheim (10054)
Central Admixture Pharmacy Services (10051)
Chattem (10018)
DSM (10052)
Epic Pharma (10037)
Eurand (10034)
Fisher (10042)
Fisher (10046)
Fisher (10047)
Halo (10026)
Halo (10043)
Impax (10029) (1 of 2)
Impax (10029) (2 of 2)
Janssen Ortho (10031)
Mallinckrodt (10058)
Mallinckdrodt (NA004)

(b)(4);(b)(7)(E)

Micron Technologies Inc. (10049) (2 of 2)
Noramco (10032)
Noramco (10033)
Noramco (10049) (1 of 2)
Norwich (10024)
Par (10030)
Penick (10022)
Pharmaceutics International (10027)
Pharmaform (10028)
Purdue (10044)
Sharp (10039)
Sharp Corporation (10045)
TEVA (10019)
TEVA (10020)
TEVA (10021)
Varian (10048)
VistaPharm (10038)
Watson (10041) (1 of 2)
Watson (10041) (2 of 2)
Watson (10050)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Additional Quota Letters Received as of 05-06-10
(DFN: 630-08.2)

Date

MAY 10 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 6, 2010, this section received your e-mail requesting a review of thirty-two (32) quota applications from twenty (20) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Actavis (10075)
AMRI (10092)
Aurolife (10065)
Baxter (10036)
Consolidated Technologies (10093)
Halo (10064)
Johnson Matthey (10066)
Johnson Matthey (10078)
Johnson Matthey (10079)
Johnson Matthey (10080)
Johnson Matthey (10081)
Johnson Matthey (10082)
Johnson Matthey (10083)
Johnson Matthey (10084)
Johnson Matthey (10085)
Johnson Matthey (10086)
Johnson Matthey (10087)
King (10076)
Lonza (10063)
Metrics (10088)

(b)(4);(b)(7)(E)

Norameo (10089)
Novartis (10090)
Novartis Consumer Health Lincoln (10097)
Palmetto State (10062)
Sun Pharmaceuticals (10094)
Tris Pharma, Inc. (10095)
Tris Pharma, Inc. (10096)
U.S. Pharmacopeia (10091)
Vintage (10067)
Vintage (10068)
Watson (10074 (1 of 2)
Watson (10074) (2 of 2)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Additional Quota Letters Received as of 05-10-10
(DFN: 630-08.2)

Date

MAY 1 1 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 10, 2010, this section received your e-mail requesting a review of six (06) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Ameridose, LLC (10099)
Tris Pharma, Inc (10100)
Cephalon, Inc (10101)
CIMA (10102)
CIMA (10103)
Corepharma (10104)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Additional Quota Requests as of 5-20-2010
(DFN: 630-08.2)

Date

MAY 2 4 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 20, 2010, this section received your e-mail requesting a review of twenty (20) quota applications from eighteen (18) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Hospira, Inc NC (10138)
Physicians Total Care (10139)
Endo New York (10140)
Patheon (10141)
Pharmaceutics International (10142)
Anderson Packaging, Inc. (10143)
Novartis Consumer Health (10145)
AAIPharmaceuticals (10146)
Mallinckrodt St. Louis (10147)
Nektar (10148)
Nektar (10149)
Watson (Andrx) (10152) (1 of 2)
Watson (Andrx) (10152) (2 of 2)
Watson (Andrx) (10153)
Alza Vacaville (10154)
Palmetto State (10155)
Barr New York (10158)
Vintage Generics Bideo (10159)
Vintage Pharmaceutical (10160)
DSM (10161)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject

Additional Quota Letters Received as of May 27, 2010
(DFN: 630-08.2)

Date

JUN 07 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On May 27, 2010, this section received your e-mail requesting a review of thirty-one (31) quota applications from twenty-nine (29) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Tris Pharma, Inc. (10105)
Tris Pharma, Inc. (10106)
Mediscа (10107)
Siegfried (10108)
Bilcare (10109)
Siegfried (10110)
Fisher (10111)
Novartis (10116)
Purdue (10117)
ANIP (10118)
Lehigh Valley Technologies, Inc. (10119)
Glatt Air (10121)
Cambrex (10122)
Aurolife (10123)
DSM (10124)
UPM (10125)
Coating Place Inc (10126)
Abbott Laboratories North Chicago (10127)
Watson (10128)
Watson (10129)

(b)(4);(b)(7)(E)

Noramco Delaware (10130)
Impax(10131)
Pharmedium (10132)
Cerilliant (10135)
Dispensing Solutions, Inc (10165)
Mallinckrodt Hobart (10169)
Fisher (10170)
Elite (10171)
Catalent (10172)
Patheon (10174)
AAIPharma Services (10175)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of June 7, 2010 (DFN: 630-08.2)	JUN 1 0 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On June 7, 2010, this section received your e-mail requesting a review of twenty-four (24) quota applications from twenty (20) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Sandoz (10176)
Aptuit (10177)
Pharmaceutics International (10178)
Mylan (10180)
Aurolife (10181)
B & B (10182)
B & B (10183)
TG United Liquid (10184)
Ohm Laboratories (10185)
Mallinckrodt St. Louis (10186)
Chemtos (10187)
Mylan (10188)
Mallinckrodt St. Lois (10189)
Collegium (10191)
ElSohly Laboratories (10192)
Alza (10193)
Barr (10194)
Acura (10199)
Mallinckrodt St. Louis (10201)
Sandoz (10205)

(b)(4);(b)(7)(E)

AustarPharma (10206)
Chattem (10207)
Metrics (10208)
Mylan (10209)

(b)(4);(b)(7)(E)

Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Requests as of June 11, 2010 (DFN: 630-08.2)	JUN 15 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

for Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On June 11, 2010, this section received your e-mail requesting a review of twenty (20) quota applications from nineteen (19) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Nexgen Pharma, Inc. (10212)
Mallinckrodt St. Louis (10213)
Patheon (10214)
Mikart (10215)
Emerson Resources, Inc. (10216)
Catalent (10217)
B & B (10218)
Impax (10219) (1 of 2)
Impax (10219) (2 of 2)
Hospira, Inc. NC (10220)
Watson (10221)
Watson (10222)
DSM (10226)
Johnson Matthey (10227)
Catlent (10228)
Noramco (10229)
Cambrex (10230)
Jerome Stevens (10231)
Noramco (10232)
Dispensing Solutions, Inc. (10233)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received as of June 24, 2010 (DFN: 630-08.2)	JUL 0 1 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On June 24, 2010, this section received your e-mail requesting a review of thirty-two (32) quota applications from twenty-eight (28) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Fisher Virginia (10238)
Sigma (10239)
CorePharma Wood Ave (10241)
Sandoz (formerly Geneva Pharmaceuticals, Inc) (10242)
Vintage Generics Bideo (10243)
Mylan Chestnut Ridge Road West Virginia (10244)
Mylan Chestnut Ridge Road West Virginia (10245)
Watson Utah (10247)
Axcentria (10249)
Rhodes (10250)
Neos Therapeutics, LP (formerly Pharmafab) (10251)
PalliRx, Inc. (10253)
Epic (10254)
Boehringer Ingelheim (10255)
Fisher Virginia (10256)
Johnson Matthey (10262)
Cerilliant (10263)
Rhodes (10264)
Sigma (10266)
Cody (10267)

(b)(4);(b)(7)(E)

Par (10268) (1 of 2)
Par (10268) (2 of 2)
Ortho McNeil Pharmaceutical (10269)
Alza Vacaville (10270)
Vintage Generics Bideo (10271)
Janssen Puerto Rico (10274)
Novartis Consumer Health Lincoln (10275)
Impax Pennsylvania (10276)
Collegium Pharmaceutical (10277)
KVK Tech. Inc. (10278)
Bilcare (10279)
Sure-Tech (10280)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Requests as of July 1, 2010 (DFN: 630-08.2)	JUL 06 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On July 1, 2010, this section received your e-mail requesting a review of nineteen (19) quota applications from fifteen (15) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Hospira, Inc. NC (10236)
Hospira, Inc. NC (10252)
BD Medical (10282)
Barr Laboratories (10283)
Hisamitsu California Laboratories (10284)
Coating Place Inc (10285)
Chattem (10286)
Sigma-Aldrich Research Biochemicals (10288)
AAIPharma (10291)
Wildlife Pharmaceuticals (10295)
Chattem (10296)
Chattem (10297)
Chattem (10298)
Par Pharmaceuticals (10299) (1 of 2)
Par Pharmaceuticals (10299) (2 of 2)
Epic Pharma (10300)
Cerilliant (10303)
BI Roxanne (10304)
Sharp Corporation (10305)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

Memorandum

Subject	Date
Additional Quota Letters Received by July 12, 2010 (DFN: 630-08.2)	JUL 14 2010

To

Christine A. Sannerud, Ph.D., Chief
Drug & Chemical Evaluation Section
Office of Diverison Control

From

Barbara J. Boockholdt, Chief
Regulatory Section
Office of Diversion Control

On July 12, 2010, this section received your e-mail requesting a review of twenty-five (25) quota applications from twenty-four (24) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Novartis Consumer Health Lincoln (10306)
VistaPharm (10307)
Siemens Healthcare Diagnostics Inc. (10308)
Eon/Sandoz (10309)
King (10310)
Mallinckrodt (10311)
Catalent (10312)
Siegfried (10313)
Amerisource (10317)
Hospira, Inc. NC (10318)
Ameridose, LLC (10319)
Ameridose, LLC (10320)
Noramco Delaware (10321)
Paddock (10323)
Cambrex (10324)
Medisca (10326)
CorePharma (10327)
Actavis (10328)
Cody (10330)
Biosite (10331)

(b)(4);(b)(7)(E)

Norac (10333)
Watson (10334)
3M (10336)
Fisher (10337)
Sun Pharmaceuticals (10338)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)